Donepezil increases resistance to induced seizures in a mouse model of Dravet syndrome

22Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

Abstract

De novo loss-of-function mutations in SCN1A are the main cause of Dravet syndrome, a catastrophic encephalopathy characterized by recurrent early-life febrile seizures, a number of other afebrile seizure types that are often refractory to treatment, and behavioral abnormalities including social deficits, motor dysfunction, and cognitive impairment. We previously demonstrated that the reversible acetylcholinesterase inhibitor, Huperzine A, increases seizure resistance in Scn1a mutants. In the present study, we evaluated the therapeutic potential of donepezil, a reversible acetylcholinesterase inhibitor approved by the Food and Drug Administration, in a mouse model of Dravet syndrome (Scn1a+/−). We found that donepezil conferred robust protection against induced seizures in Scn1a+/− mutants.

Cite

CITATION STYLE

APA

Wong, J. C., Thelin, J. T., & Escayg, A. (2019). Donepezil increases resistance to induced seizures in a mouse model of Dravet syndrome. Annals of Clinical and Translational Neurology, 6(8), 1566–1571. https://doi.org/10.1002/acn3.50848

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free